Ausdhi

Ausdhi is a biotechnology company focused on the discovery and development of next-generation small molecule inhibitors for the treatment of cancer and inflammatory diseases. Utilizing a proprietary structure-based drug design platform, the company targets specific kinases including the TAM family (Tyro3, Axl, and MerTK) and ALK/ROS1/LTK to address therapeutic resistance and improve patient outcomes. Their lead research programs are primarily in the preclinical stage, targeting indications such as non-small cell lung cancer and acute myeloid leukemia. Ausdhi aims to translate complex structural biology insights into potent, selective clinical candidates. The company is headquartered in Salt Lake City and maintains strong ties to academic research institutions for its development programs.